MRL Ventures Fund

Type

Venture Capital

Status

Active

Location

Cambridge, United States

Total investments

45

Average round size

57M

Portfolio companies

28

Rounds per year

4.50

Lead investments

3

Follow on index

0.38

Exits

7

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife ScienceTherapeuticsClinical TrialsEmergency Medicine

Summary

The main department of described VC is located in the Cambridge. The venture was found in North America in United States.

We also calculated 3 valuable employees in our database.

The fund is generally included in 2-6 deals every year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Comparing to the other companies, this MRL Ventures Fund performs on 7 percentage points more the average number of lead investments. The top amount of exits for fund were in 2018. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Alector, Entrada Therapeutics, Carisma Therapeutics Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Health Care, Medical Device.

The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the MRL Ventures Fund, startups are often financed by Atlas Venture, Amgen Ventures, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Atlas Venture, Amgen Ventures, SR One. In the next rounds fund is usually obtained by GV, Fidelity Management and Research Company, Atlas Venture.

Show more

Investor highlights

Industry focus
Medtech
Stage focus
Seed
Geo focus
Generalist
Check size
Up to 25M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
45
Lead investments
3
Exits
7
Rounds per year
4.50
Follow on index
0.38
Investments by industry
  • Biotechnology (41)
  • Therapeutics (26)
  • Health Care (21)
  • Medical (19)
  • Life Science (14)
  • Show 14 more
Investments by region
  • United States (41)
  • Netherlands (2)
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
6
Avg. valuation at time of investment
15M
Group Appearance index
1.00
Avg. company exit year
11
Avg. multiplicator
3.34
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Aktis Oncology 25 Aug 2022 Biotechnology, Life Science Early Stage Venture 84M United States, Massachusetts, Boston
InduPro 13 Jun 2024 Early Stage Venture 85M United States, Washington, Seattle

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.